Erythrocyte membrane phosphorylation in untreated and in etretinate-treated psoriatic patients.
Levels of phosphorylation were decreased in bands 2 to 2.1, 2.9 to 3 and 4.5 to 4.8 of erythrocyte membranes from psoriatic patients compared with control values. In addition, higher than control levels of 32P were incorporated into a new polypeptide band (mol.wt. 18-20,000 daltons) of red cell membranes from patients. Uptake of 32P by these bands returned towards normal after the patients received oral etretinate treatment. These results suggest there is a generalized plasma membrane defect in psoriasis and that etretinate may affect the metabolism of red cell membrane proteins.
D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism*; D005050:Etretinate / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010748:Phosphopeptides / Q000097:blood*; D010766:Phosphorylation; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy
D010748:Phosphopeptides; D005050:Etretinate; D000255:Adenosine Triphosphate